ZA201201703B - Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors - Google Patents

Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors

Info

Publication number
ZA201201703B
ZA201201703B ZA2012/01703A ZA201201703A ZA201201703B ZA 201201703 B ZA201201703 B ZA 201201703B ZA 2012/01703 A ZA2012/01703 A ZA 2012/01703A ZA 201201703 A ZA201201703 A ZA 201201703A ZA 201201703 B ZA201201703 B ZA 201201703B
Authority
ZA
South Africa
Prior art keywords
inhibitors
tyrosine kinase
protein tyrosine
pyrimidine derivatives
pyrimidine
Prior art date
Application number
ZA2012/01703A
Other languages
English (en)
Inventor
Heinz Stadtmueller
Loannis Sapountzis
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43048878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201201703(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ZA201201703B publication Critical patent/ZA201201703B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2012/01703A 2009-10-02 2012-03-08 Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors ZA201201703B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09172026 2009-10-02
EP10172460 2010-08-11
PCT/EP2010/064628 WO2011039344A1 (en) 2009-10-02 2010-10-01 Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors

Publications (1)

Publication Number Publication Date
ZA201201703B true ZA201201703B (en) 2014-05-28

Family

ID=43048878

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/01703A ZA201201703B (en) 2009-10-02 2012-03-08 Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors

Country Status (25)

Country Link
US (1) US8466155B2 (forum.php)
EP (1) EP2483249B1 (forum.php)
JP (1) JP5702390B2 (forum.php)
KR (1) KR20120092617A (forum.php)
CN (1) CN102695700A (forum.php)
AP (1) AP2012006166A0 (forum.php)
AR (1) AR078513A1 (forum.php)
AU (1) AU2010302648A1 (forum.php)
BR (1) BR112012007300A2 (forum.php)
CA (1) CA2775418A1 (forum.php)
CL (1) CL2012000825A1 (forum.php)
EA (1) EA201200552A1 (forum.php)
EC (1) ECSP12011830A (forum.php)
IL (1) IL218543A0 (forum.php)
IN (1) IN2012DN02714A (forum.php)
MA (1) MA33606B1 (forum.php)
MX (1) MX2012003101A (forum.php)
NZ (1) NZ598614A (forum.php)
PE (1) PE20121431A1 (forum.php)
PH (1) PH12012500527A1 (forum.php)
TN (1) TN2012000142A1 (forum.php)
TW (1) TW201124386A (forum.php)
UY (1) UY32916A (forum.php)
WO (1) WO2011039344A1 (forum.php)
ZA (1) ZA201201703B (forum.php)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
ES2691673T3 (es) 2011-02-17 2018-11-28 Cancer Therapeutics Crc Pty Limited Inhibidores de Fak
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
JP2015502958A (ja) * 2011-12-09 2015-01-29 オンコメッド ファーマシューティカルズ インコーポレイテッド がんの処置のための併用療法
JPWO2013146963A1 (ja) * 2012-03-28 2015-12-14 武田薬品工業株式会社 複素環化合物
PT3495367T (pt) 2012-06-13 2020-11-12 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
WO2014190207A1 (en) 2013-05-22 2014-11-27 The Regents Of The University Of California Aurora kinase inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220100879A (ko) 2019-10-14 2022-07-18 인사이트 코포레이션 Fgfr 저해제로서의 이환식 헤테로사이클
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
RS94703A (en) * 2001-05-29 2007-02-05 Schering Aktiengesellschaft, Cdk inhibiting pyrimidines, production thereof and their use as medicaments
EP1438053B1 (de) 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
WO2003076437A1 (de) * 2002-03-11 2003-09-18 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
WO2005118544A2 (en) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2006034872A1 (de) * 2004-09-29 2006-04-06 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
EP1966207A2 (en) * 2005-12-21 2008-09-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
PE20080068A1 (es) 2006-05-15 2008-03-17 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
GB0619343D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
WO2008077885A2 (en) * 2006-12-22 2008-07-03 Boehringer Ingelheim International Gmbh 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer
KR101424847B1 (ko) 2007-04-16 2016-07-08 허치슨 메디파르마 엔터프라이즈 리미티드 피리미딘 유도체
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI458721B (zh) 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
CA2760794C (en) 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders

Also Published As

Publication number Publication date
PH12012500527A1 (en) 2012-10-22
MA33606B1 (fr) 2012-09-01
EA201200552A1 (ru) 2013-03-29
AU2010302648A1 (en) 2012-04-05
TW201124386A (en) 2011-07-16
UY32916A (es) 2011-04-29
US8466155B2 (en) 2013-06-18
CN102695700A (zh) 2012-09-26
JP2013506636A (ja) 2013-02-28
PE20121431A1 (es) 2012-11-10
AP2012006166A0 (en) 2012-04-30
AR078513A1 (es) 2011-11-16
CL2012000825A1 (es) 2012-08-24
ECSP12011830A (es) 2012-06-29
US20110237598A1 (en) 2011-09-29
JP5702390B2 (ja) 2015-04-15
MX2012003101A (es) 2012-04-11
WO2011039344A1 (en) 2011-04-07
CA2775418A1 (en) 2011-04-07
NZ598614A (en) 2013-08-30
KR20120092617A (ko) 2012-08-21
TN2012000142A1 (en) 2013-09-19
IN2012DN02714A (forum.php) 2015-09-11
IL218543A0 (en) 2012-05-31
EP2483249B1 (en) 2015-12-23
BR112012007300A2 (pt) 2017-11-07
EP2483249A1 (en) 2012-08-08

Similar Documents

Publication Publication Date Title
ZA201201703B (en) Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors
HUS1900014I1 (hu) Proteinkináz inhibitorok
PL2610256T3 (pl) Pochodne pirymidyny jako inhibitory kinaz białkowych
ZA201100344B (en) Pyrimidine derivatives as kinase inhibitors
PT2200436E (pt) Pirimidinilaminas substituídas como inibidoras da proteína quinase
IL206416A0 (en) Benzofuropyrimidinones as protein kinase inhibitors
PL2203449T3 (pl) Heterocykliczne związki bicykliczne jako inhibitory białkowej kinazy tyrozynowej
PT2197880E (pt) Compostos heterocíclicos bicíclicos como inibidores da proteína tirosina cinase
ZA201001512B (en) Inhibitors of protein tyrosine kinase activity
PL2193133T3 (pl) Imidazolotiadiazole do stosowania jako inhibitory kinazy białkowej
ZA201201978B (en) Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
ZA200909223B (en) Pyrimidine derivatives useful as raf kinase inhibitors
PL2252597T3 (pl) Pochodne pirazyny i ich zastosowanie jako inhibitorów kinaz białkowych
IL210073A0 (en) Protein kinase inhibitors
ZA201005868B (en) Inhibitors of protein tyrosine kinase activity
PT2231642E (pt) Pirimidinas como inibidores de quinase
IL210069A0 (en) Protein kinase inhibitors
IL218790A0 (en) Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
EP2247185A4 (en) INHIBITORS OF TYROSINE KINASE
ZA200807490B (en) Thiazolyldihydroindazole derivatives as protein kinase inhibitors
HK1150829A (en) Pyrimidine derivatives as kinase inhibitors
GB0807642D0 (en) IKK- serine-threonine protein kinase inhibitors